Recent insider open-market stock purchases demonstrate continued confidence in the Company CAESAREA, Israel, June 18, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the Company's management, will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, ...

IceCure Medical Ltd. (ICCM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a chan ...

Demonstrates public health importance of assessing ProSense®'s potential to offer optimal treatment that benefits women with early-stage breast cancer Patients, patient advocacy groups, doctors, and the general public will be welcome to participate and comment in the open public hearing IceCure welcomes a transparent public forum to share ICE3 study results and show how ProSense® cryoablation could potentially offer a minimally invasive alternative treatment to women diagnosed with early-stage breast cancer ...

IceCure Medical Ltd (NASDAQ:ICCM) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - VP, Business Development & Global Marketing Ronen Tsimerman - Chief Financial Officer & Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Ben Haynor - Lake Street Capital Markets Yi Chen - H.C. Wainwright Operator Good mor ...

Exhibit 99.1 IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 ● 30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets ● Major milestones achieved: O Completion of landmark ICE3 trial for breast cancer O Positive final ICE3 trial data ● Awaiting FDA Decision ● Independent studies performed globally continue to demonstrate ProSense®’s efficacy and safety across numerous indications ● Conference call t ...

30% sales growth reflects continued adoption of ProSense® in the U.S. and other global markets Major milestones achieved: - Completion of landmark ICE3 trial for breast cancer - Positive final ICE3 trial data Awaiting FDA Decision Independent studies performed globally continue to demonstrate ProSense®'s efficacy and safety across numerous indications Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, May 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceC ...

文章核心观点 - 公司IceCure Medical Ltd.开发了ProSense®系统,这是一种微创冷冻消融技术,可以通过冻结的方式破坏肿瘤,作为外科手术切除肿瘤的替代方案 [1][2] - 公司将于2024年5月28日发布2024年第一季度的财务和运营业绩,并在当天召开电话会议讨论相关结果和其他公司发展动态 [1] 公司概况 - IceCure Medical是一家在纳斯达克上市的公司,开发和销售ProSense®系统 [2] - ProSense®是一种基于液氮的微创冷冻消融疗法,主要用于治疗乳腺、肾脏、骨骼和肺部的良性和恶性肿瘤 [2] - 该系统是一种安全有效的外科手术切除肿瘤的替代方案,操作简单,过程较短 [2] - 该系统已在美国、欧洲和中国获得相关适应症的批准和销售 [2]

IceCure Medical (ICCM)的ProSense系统 - IceCure Medical (ICCM)最近向FDA提交了最终数据，请求市场授权其ProSense系统[1] - ProSense旨在提供冷冻消融技术，可在20-40分钟内治疗乳腺癌[1] - ProSense已在美国获得清关，系统还获得了其他适应症的清关，包括治疗乳腺的良性肿瘤以及肾脏和肝脏的肿瘤[6] - 在2022年，FDA拒绝了IceCure对ProSense进行新分类的请求，但在2024年1月，FDA同意重新打开新分类文件，并积极回应，为IceCure提供了可能的清关途径[7] - 公司提交了ICE3研究的五年随访数据，FDA还收到了来自真实世界来源的数据，如独立第三方研究结果和市场后使用情况[8] - 根据数据，ProSense冷冻消融和激素治疗亚组中96.3%的患者在五年随访评估时被认为没有局部复发[10] 冷冻消融设备市场 - 全球冷冻消融设备市场规模在2022年超过6.9亿美元，并预计到2032年将达到超过15亿美元，增长率为8.5%[11] - 冷冻消融设备的需求预计将受到患者和外科医生越来越倾向于微创治疗程序的推动，因为这些程序具有更快的康复时间、更少的停工时间和增加患者舒适度的好处[12]

销售收入和净利润 - IceCure Medical Ltd. 2023年12月31日的销售收入为320万美元，同比增长26%[30] - IceCure Medical 2023年净亏损为1470万美元，同比减少14%[35] 毛利和现金储备 - 2023年12月31日的总毛利为130万美元，毛利率为40%[32] - IceCure Medical截至2023年12月31日的现金及现金等价物约为1110万美元[36] 筹资和感谢 - IceCure Medical在2024年第一季度通过ATM筹集了约300万美元[37] - 公司表示感谢所有参与I3研究和其家人的患者[54] - 公司希望通过ProSense plus治疗，帮助女性摆脱手术疤痕，享受健康生活[54] - 公司感谢所有支持帮助将一种迫切需要的微创解决方案带给早期乳腺癌女性的股东们[54]

Exhibit 99.1 IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense in breast cancer indication CAESAREA, Israel, April 3, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSen ...